+967-774203774 [email protected]
العربية

Decoding Bone Mineral Density Conditions: Osteoporosis & Beyond

Updated: Feb 2026 70 Views
Illustration of bone mineral density - Dr. Mohammed Hutaif

Key Medical Takeaway

In this comprehensive guide, we discuss everything you need to know about Decoding Bone Mineral Density Conditions: Osteoporosis & Beyond. Bone mineral density conditions primarily include osteoporosis and osteopenia. Osteoporosis signifies an age-related decrease in bone mass, defined by lumbar density 2.5 or more standard deviations below a healthy 25-year-old’s peak bone mass (T-score). Osteopenia is when bone density is 1.0–2.5 standard deviations less. Both are quantitative defects that increase fracture risk.

  1. Conditions of bone mineral density

  2. Bone mass is regulated by rates of deposition and withdrawal ( Fig.
    1.20 ).
  3. Osteoporosis
  4. Age-related decrease in bone mass
  5. Usually associated with estrogen loss in postmenopausal women ( Fig. 1.21)
  6. A quantitative, not qualitative, defect
  7. Mineralization remains normal
  8. World Health Organization’s definition
  9. Lumbar (L2–L4) density is 2.5 or more standard deviations less than mean peak bone mass of a healthy 25-year-old (T-score). 2. Osteopenia: bone density is 1.0–2.5 standard deviations less than the mean peak bone mass of a healthy 25-year-old. 4. Responsible for more than 1 million fractures per year
  10. Fractures of the vertebral body are most common.
  11. History of osteoporotic vertebral compression fractures are strongly predictive of subsequent vertebral fracture.
  12. After initial vertebral fracture, the risk for a second vertebral fracture is 20%.
  13. Vertebral compression fracture is associated with increased mortality rate.
  14. Incidence of vertebral compression fractures is higher among men than women.
  15. Lifetime risk of fracture in white women after 50 years of age: 75%
  16. The risk for hip fracture is 15%–20%.
  17. Risk factors ( Box 1.2)
  18. Cancellous bone is most affected.
  19. Clinical features
  20. Kyphosis and vertebral fractures
  21. Compression fractures of T11–L1 that create anterior wedge-shaped defects or centrally depressed codfish vertebrae
  22. Hip fractures
  23. Distal radius fractures

  24. Type I osteoporosis (postmenopausal)

  25. Primarily affects trabecular bone
  26. Vertebral and distal radius fractures common
  27. Type II osteoporosis (age-related)
  28. Patients older than 75 years
  29. Affects both trabecular and cortical bone
  30. Related to poor calcium absorption
  31. Hip and pelvic fractures are common.
  32. Laboratory studies
  33. Obtained to rule out secondary causes of low bone mass:
  34. Vitamin D deficiency, hyperthyroidism, hyperparathyroidism, Cushing syndrome, hematologic disorders, malignancy

  35. Complete blood cell count; measurements of serum calcium, phosphorus, 25(OH)D, alkaline phosphatase, liver enzymes, creatinine, and total protein and albumin levels; and measurement of 24-hour urinary calcium excretion

  36. Results of these studies are usually unremarkable in osteoporosis.
  37. Plain radiographs not helpful unless bone loss exceeds 30%
  38. Special studies
  39. Single-photon (appendicular) absorptiometry
  40. Double-photon (axial) absorptiometry
  41. Quantitative computed tomography (CT)
  42. Dual-energy x-ray absorptiometry (DEXA) 1. #### Most accurate with less radiation
  43. Biopsy
  44. After tetracycline labeling
  45. To evaluate the severity of osteoporosis and identify osteomalacia
  46. Histologic changes
  47. Thinning trabeculae
  48. Decreased osteon size
  49. Enlarged haversian and marrow spaces
  50. Treatment ( Fig. 1.22)
  51. Physical activity
  52. Supplements: 1000–1500 mg calcium plus 400–800 IU of vitamin D per day 1. More effective in type II (age-related) osteoporosis
  53. Bisphosphonates
  54. Inhibit osteoclastic bone resorption— direct anabolic effect on bone
  55. Categorized into two classes on the basis of presence or absence of a nitrogen side group:

  56. Nitrogen-containing bisphosphonates—up to 1000-fold more potent in their antiresorptive activity

  57. Zoledronic acid (Zometa) and alendronate (Fosamax)

  58. Inhibit protein prenylation within the mevalonate pathway, blocking farnesyl pyrophosphate synthase

  59. Results in a loss of GTPase formation, which is needed for ruffled border formation and cell survival

  60. Non–nitrogen-containing bisphosphonates
  61. Metabolized into a nonfunctional ATP analogue, inducing apoptosis
  62. Decreases skeletal
    events in multiple myeloma

  63. Associated with osteonecrosis of the jaw

  64. Orthopaedic implications of bisphosphonate use
  65. Spine— reduced rate of spinal fusion in animal model ; withholding bisphosphonate is recommended after surgery.
  66. Hip and knee—safe for use in cementless hip arthroplasty and cemented knee arthroplasty; may decrease rate of acetabular component subsidence
    Illustration 1 for Decoding Bone Mineral Density Conditions: Osteoporosis & Beyond
    --- FIG. 1.20 Four mechanisms of bone mass regulation.
    From Netter FH: CIBA collection of medical illustrations, vol 8: Musculoskeletal system, part I: Anatomy, physiology and developmental disorders, Basel, Switzerland, 1987, CIBA, p 181.
  67. Fracture healing—no good data to recommend for or against use; will decrease future fracture risk
  68. Denosumab is a monoclonal antibody that targets and inhibits RANKL binding to the RANK receptor, which is found on osteoclasts.
  69. Other drugs (e.g., intramuscular calcitonin) may be helpful.
  70. Expensive and may cause hypersensitivity reactions
  71. Efficacy of bone augmentation with PTH, growth factors, prostaglandin inhibitors, and other therapies remains to be determined.
  72. Prophylaxis for patients at risk for osteoporosis
  73. Diet with adequate calcium intake
  74. Weight-bearing exercise program
    Illustration 2 for Decoding Bone Mineral Density Conditions: Osteoporosis & Beyond
    --- FIG. 1.21 Age-related changes in density and architecture of human trabecular bone from the lumbar spine. With progressive age, there is a quantitative decrease in bone, but the mineralization (qualitative) remains the same. B ox 1 . 2 R i s k F a c t or s for t h e Dev el opmen t of O s t eopor os i s 1. White race, female gender, northern European descent (fair skin and hair)
  75. Sedentary lifestyle
  76. Thinness
  77. Smoking
  78. Heavy drinking
  79. Phenytoin (impairs vitamin D metabolism)
  80. Diet low in calcium and vitamin D
  81. History of breastfeeding
  82. Positive family history of osteoporosis
    • Premature menopause
    From Keaveney TM, Hayes WC: Mechanical properties of cortical and trabecular bone, Bone 7:285–344, 1993.
  83. Estrogen therapy evaluation at menopause
  84. Other causes of decreased mineral density
  85. Idiopathic transient osteoporosis of the hip
  86. Uncommon; diagnosis of exclusion
  87. Most common during third trimester of pregnancy in women but can occur in men
  88. Groin pain, limited ROM, and localized osteopenia without a history of trauma
  89. Treatment: analgesics and limited weight bearing
  90. Generally self-limiting and tends to resolve spontaneously after 6–8 months
  91. Stress fractures may occur.
  92. Joint space remains preserved on radiographs.
  93. Osteomalacia
  94. Femoral neck fractures are common.
  95. Qualitative defect

  96. Defect of mineralization results in a large amount of unmineralized osteoid.

  97. Causes:
  98. Vitamin D–deficient diet
  99. GI disorders
  100. Renal osteodystrophy
  101. Certain drugs
  102. Aluminum-containing phosphate-binding antacids; aluminum deposition in bone prevents mineralization
  103. Phenytoin (Dilantin)
    Illustration 3 for Decoding Bone Mineral Density Conditions: Osteoporosis & Beyond
    --- FIG. 1.22 Treatment options for osteoporosis. Adapted from Simon SR, editor: Orthopaedic basic science, Rosemont, IL, 1994, American Academy of Orthopaedic Surgeons, p 174.
  104. Alcoholism
  105. Radiographic findings
  106. Looser zones (microscopic stress fractures)
  107. Other fractures
  108. Biconcave vertebral bodies
  109. Trefoil pelvis
  110. Biopsy (transiliac) required for diagnosis
  111. Widened osteoid seams are histologic
    findings.
  112. Treatment: usually includes large doses of vitamin D
  113. Osteoporosis and osteomalacia are compared in Fig. 1.23.
  114. Scurvy
  115. Vitamin C (ascorbic acid) deficiency
  116. Produces a decrease in chondroitin sulfate synthesis
  117. Leads to defective collagen growth and repair
    Illustration 4 for Decoding Bone Mineral Density Conditions: Osteoporosis & Beyond
    Illustration 5 for Decoding Bone Mineral Density Conditions: Osteoporosis & Beyond FIG. 1.23 Comparison of osteoporosis and osteomalacia.
    From Netter FH: CIBA collection of medical illustrations, vol 8: Musculoskeletal system, part I: Anatomy, physiology and developmental disorders, Basel, Switzerland, 1987, CIBA, p 228.
  118. Also leads to impaired intracellular hydroxylation of collagen peptides
  119. Clinical features:
  120. Fatigue
  121. Gum bleeding
  122. Ecchymosis
  123. Joint effusions
  124. Iron deficiency
  125. Radiographic findings:
  126. May include thin cortices and trabeculae and metaphyseal clefts (corner sign)
  127. Laboratory studies: normal results
  128. Histologic features
  129. Primary trabeculae replaced with granulation tissue
  130. Areas of hemorrhage

  131. Widening of the zone of provisional calcification in the physis

  132. Greatest effect on bone formation in the metaphysis
  133. Marrow packing disorders
  134. Myeloma, leukemia, and other such disorders can cause osteopenia.
  135. Lead poisoning
  136. Results in short stature and reduced bone density
  137. Lead alters the chondrocyte response to PTH-related protein and TGF-β.
  138. Increased osteodensity
  139. Osteopetrosis (marble bone disease)
  140. Result of decreased osteoclast (and chondroclast) function: failure of bone resorption
  141. Osteopoikilosis (spotted bone disease)
  142. Islands of deep cortical bone appear within the medullary cavity and the cancellous bone of the long bones
  143. Especially in the hands and feet
  144. These areas are usually asymptomatic
  145. This disease is accompanied by no known incidence of malignant degeneration.
  146. Paget disease of bone (osteitis deformans)
  147. Elevated serum alkaline phosphatase and urinary
Table of Contents
Dr. Mohammed Hutaif
Written & Medically Reviewed by
Dr. Mohammed Hutaif
Consultant Orthopedic & Spine Surgeon
Keywords
Prof. Mohammed Hutaif Orthopedic Surgeon Yemen bone mineral density decoding bone mineral mineral density conditions density conditions osteoporosis
WhatsApp Facebook